Floatz Rating
B57/100
Confidence
Indicative
Sponsor
AIO-Studien-gGmbH
Modality
Small molecule
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03044587CT.gov Nal-IRI With 5-fluorouracil (5-FU) and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Biliary-tract Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Bile Duct Adenocarcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Irinotecan (this asset) | AIO-Studien-gGmbH | P2 | B · 57 |
| Atezolizumab | Georgetown University | P3 | BB |
| Cis-Diamminedichloroplatinum Ii | AIO-Studien-gGmbH | P2 | B |
| Fluorouracilum | AIO-Studien-gGmbH | P2 | B |
| Cobimetinib | National Cancer Institute (NCI) | P2 | CCC |
| Immunoglobulin G1, Anti-(Human Cd Antigen Cd27) (Human Monoclonal Cdx-1127 Clone 1F5 Heavy Chain), Disulfide With Human Monoclonal Cdx-1127 Clone 1F5 .Kappa.-Chain, Dimer | National Cancer Institute (NCI) | P2 | CC |
Other indications for Irinotecan
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Rectal Cancer | — | P4 | BBB · 78 |
| Exocrine Pancreatic Carcinoma | — | P2/3 | BBB · 78 |
| Colon Adenocarcinoma | — | P3 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- AtezolizumabGeorgetown UniversityBB
- Cis-Diamminedichloroplatinum IiAIO-Studien-gGmbHB
- FluorouracilumAIO-Studien-gGmbHB
- CobimetinibNational Cancer Institute (NCI)CCC
- Immunoglobulin G1, Anti-(Human Cd Antigen Cd27) (Human Monoclonal Cdx-1127 Clone 1F5 Heavy Chain), Disulfide With Human Monoclonal Cdx-1127 Clone 1F5 .Kappa.-Chain, DimerNational Cancer Institute (NCI)CC
Citation
Floatz Terminal. Irinotecan in Bile Duct Adenocarcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/irinotecan-bile-duct-adenocarcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →